Prelude Capital Management’s MediciNova MNOV Stock Holding History

Prelude Capital Management’s Portfolio MNOV Stock Details MNOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-30,500	Closed	-$160K	–	1716
2020 Q4	$160K	Buy	+30,500	New	+$175K	﹤0.01%	1147

Other funds holding MNOV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Prelude Capital Management's MNOV Position: Q1 2021 in Review

Prelude Capital Management sold out of MediciNova (MNOV) in Q1 2021, closing a stake of 30,500 shares — an estimated $160K sold.

Prelude Capital Management first reported a position in MNOV in Q4 2020 and held it in 1 quarter. The position peaked at $160K in Q4 2020. 60 funds tracked by Wall St. Rank hold MNOV as of Q1 2021.

Prelude Capital Management reported no remaining MediciNova position as of Q1 2021 after selling out during the quarter.
Prelude Capital Management sold 30,500 MediciNova shares in Q1 2021, an estimated $160K.
Prelude Capital Management first reported a position in MediciNova in Q4 2020 and held it in 1 quarter.
Prelude Capital Management's MediciNova position peaked at $160K in Q4 2020.
60 funds tracked by Wall St. Rank held MediciNova as of Q1 2021.

Based on Prelude Capital Management's 13F filing for Q1 2021, filed 17 May 2021.